Annual Accounts Receivable
$16.25 M
+$10.41 M+178.52%
31 December 2023
Summary:
Cidara Therapeutics annual accounts receivable is currently $16.25 million, with the most recent change of +$10.41 million (+178.52%) on 31 December 2023. During the last 3 years, it has risen by +$5.07 million (+45.38%). CDTX annual accounts receivable is now at all-time high.CDTX Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Receivable
$1.70 M
-$650.00 K-27.67%
30 September 2024
Summary:
Cidara Therapeutics quarterly accounts receivable is currently $1.70 million, with the most recent change of -$650.00 thousand (-27.67%) on 30 September 2024. Over the past year, it has dropped by -$1.16 million (-40.49%). CDTX quarterly accounts receivable is now -93.42% below its all-time high of $25.83 million, reached on 31 March 2023.CDTX Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CDTX Accounts Receivable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +178.5% | -40.5% |
| 3 y3 years | +45.4% | -56.1% |
| 5 y5 years | +532.9% | - |
CDTX Accounts Receivable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +203.3% | -93.4% | at low |
| 5 y | 5 years | at high | >+9999.0% | -93.4% | >+9999.0% |
| alltime | all time | at high | >+9999.0% | -93.4% |
Cidara Therapeutics Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $1.70 M(-27.7%) |
| June 2024 | - | $2.35 M(-67.7%) |
| Mar 2024 | - | $7.28 M(-55.2%) |
| Dec 2023 | $16.25 M(+178.5%) | $16.25 M(+469.0%) |
| Sept 2023 | - | $2.85 M(-47.9%) |
| June 2023 | - | $5.48 M(-78.8%) |
| Mar 2023 | - | $25.83 M(+342.8%) |
| Dec 2022 | $5.83 M(+8.9%) | $5.83 M(+15.7%) |
| Sept 2022 | - | $5.04 M(+4.3%) |
| June 2022 | - | $4.83 M(-45.0%) |
| Mar 2022 | - | $8.78 M(+64.0%) |
| Dec 2021 | $5.36 M | $5.36 M(+38.3%) |
| Sept 2021 | - | $3.87 M(+22.6%) |
| Date | Annual | Quarterly |
|---|---|---|
| June 2021 | - | $3.16 M(>+9900.0%) |
| Mar 2021 | - | $11.00 K(-99.9%) |
| Dec 2020 | $11.18 M(>+9900.0%) | $11.18 M(+71.4%) |
| Sept 2020 | - | $6.52 M(+9.5%) |
| June 2020 | - | $5.95 M(-5.6%) |
| Mar 2020 | - | $6.31 M(>+9900.0%) |
| Dec 2019 | $10.00 K(-99.6%) | $10.00 K(-99.6%) |
| Dec 2018 | $2.57 M(+699.7%) | $2.57 M(>+9900.0%) |
| Sept 2018 | - | $0.00(-100.0%) |
| June 2018 | - | $41.00 K(-85.8%) |
| Mar 2018 | - | $288.00 K(-10.3%) |
| Dec 2017 | $321.00 K | $321.00 K(0.0%) |
| Sept 2017 | - | $321.00 K(+49.3%) |
| June 2017 | - | $215.00 K |
FAQ
- What is Cidara Therapeutics annual accounts receivable?
- What is the all time high annual accounts receivable for Cidara Therapeutics?
- What is Cidara Therapeutics annual accounts receivable year-on-year change?
- What is Cidara Therapeutics quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Cidara Therapeutics?
- What is Cidara Therapeutics quarterly accounts receivable year-on-year change?
What is Cidara Therapeutics annual accounts receivable?
The current annual accounts receivable of CDTX is $16.25 M
What is the all time high annual accounts receivable for Cidara Therapeutics?
Cidara Therapeutics all-time high annual accounts receivable is $16.25 M
What is Cidara Therapeutics annual accounts receivable year-on-year change?
Over the past year, CDTX annual accounts receivable has changed by +$10.41 M (+178.52%)
What is Cidara Therapeutics quarterly accounts receivable?
The current quarterly accounts receivable of CDTX is $1.70 M
What is the all time high quarterly accounts receivable for Cidara Therapeutics?
Cidara Therapeutics all-time high quarterly accounts receivable is $25.83 M
What is Cidara Therapeutics quarterly accounts receivable year-on-year change?
Over the past year, CDTX quarterly accounts receivable has changed by -$1.16 M (-40.49%)